Chronic Phase News Today

Welcome to the whole story. Im anderson cooper, after vice president kamala harris became the democratic nominee, she launched an aggressive campaign to reintroduce herself to the country but with the election looming, many remain undecided and are looking at where harris stands on the issues that matter to them before casting their ballots. Over the next hour, cnns audie cornish looks at harriss record and her promises on five key issues in this election reproductive rights immigration, foreign...

MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for...

Updated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria patients from Phase III APPLY-PNH and APPOINT-PNH studies Head-to-head data from Phase III... | May 11, 2023

Updated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria (PNH) patients from Phase III APPLY-PNH and APPOINT-PNH studies Head-to-head data from Phase III ASCEMBL trial

Novartis Scemblix®, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least

Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96...

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial

Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-week

This 3D bioprinting technology, developed by Tel Aviv University was tested on mice with both acute and chronic paralysis. The results from the tests showed that all mice with acute paralysis regained the ability to walk. The success rate in mice with chronic paralysis was 80%.